In pharmaceutical and medical device litigation, the strength of a case increasingly depends on more than clinical records and expert testimony. Plaintiffs tell their story online, often in detail, long before a deposition ever happens. What they post, when they post it, and how it compares to their claimed injuries can shape case strategy at every stage, from early assessment through trial.
For legal teams managing mass tort and MDL dockets, the question is no longer whether to look at plaintiff social media. It is whether the way that evidence gets collected can hold up once it matters most.
The Discovery Gap in Pharma and Device Litigation
Plaintiffs’ counsel in mass tort and MDL matters have grown more sophisticated about managing a plaintiff’s public presence. At the same time, defense teams are often working with general research tools, junior staff conducting manual searches, or a patchwork of past approaches that were never built for litigation at this scale.
That gap creates real risk. A plaintiff’s activity might be entirely consistent with a serious injury narrative, or it might tell a different story. Either way, the value of that information depends on how thoroughly it was found and how well the collection process can withstand a challenge later in the case.
Why Standard Web Searches Fall Short
A standard search of a plaintiff’s name rarely tells the full story. People manage their public presence carefully, and plaintiffs involved in litigation often do so more than most. Alias accounts, maiden names, nicknames, and platforms outside the usual handful of major networks routinely hold information that a surface-level search misses entirely.
There is also a defensibility problem. Ad hoc collection, without documentation of what was searched, when, and how, can leave a legal team unable to explain their own evidence if opposing counsel challenges its authenticity or the method used to gather it. In litigation of this scale, that is not a small gap to have.
What Social Media Discovery Can Look Like
- A plaintiff claiming permanent mobility loss from a hip implant shares hiking photos on a publicly available account.Â
- A plaintiff in a pharmaceutical MDL posts about symptoms that predate the alleged exposure window or product use dates.
- Membership in a plaintiff-recruitment group shapes how an injury narrative gets framed before litigation begins.Â
- A plaintiff who names an alternative cause or reason for a condition in a public post or blog.
What a Defensible Process Looks Like
A defensible approach to social media discovery rests on a few consistent elements:
- Comprehensive search. Searching across a wide range of platforms, not just the largest and most obvious ones, surfaces accounts and content that narrower searches miss.
- Analyst-led review. Software alone cannot reliably confirm that an alias account or associated profile belongs to the right person. Experienced review adds the context and judgment that automated tools cannot.
- Authentication and chain of custody. Multiple personal identifiers and documented preservation techniques secure each finding as it appeared at capture and secure the digital chain of custody to give a legal team confidence that the evidence will hold up to scrutiny.
- Methodology aligned with recognized standards. Following established eDiscovery and authentication frameworks gives the resulting work product a foundation that can be explained and defended, not just produced.
- Ethical collection. Findings are gathered without deception, friend requests, or access to private accounts, avoiding the pretexting risks that can turn counsel into a witness to their own collection.Â
Where This Fits in the Litigation Lifecycle
Social media discovery can assist at multiple points in a pharmaceutical or medical device case. Early in a matter, it can help a legal team assess a claim’s credibility and calibrate case strategy accordingly. Later, it can support deposition preparation, inform settlement posture, or provide material relevant to expert review. In active MDL discovery, where hundreds or thousands of claims may be moving through the same process simultaneously, having a consistent, repeatable, and defensible methodology matters just as much as any single finding.
A Foundation Worth Getting Right
As social media discovery becomes a standard part of pharmaceutical and medical device defense, the legal teams best positioned are the ones treating it as seriously as any other category of evidence. That means a documented process, experienced review, and a methodology built to withstand scrutiny from opposing counsel, experts, and the bench alike.
SMI Aware provides analyst-led social media discovery purpose-built for legal teams handling product liability, mass tort, and MDL matters. To learn more about how a defensible discovery process fits into your current litigation, talk to an analyst.
